Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Phase 1

Recruiting

Conditions: Recurrent
Refractory Cancer
Head and Neck Cancer
Relapse

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Cell Therapy

First Posted Date: 2023-10-23

Last Posted Date: 2024-11-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT06096038

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Phase 1

Recruiting

Conditions: Myxoid/Round Cell Liposarcoma
Synovial Sarcoma

Interventions: Drug: Fludarabine phosphate
Drug: NY-ESO-1 TCR/IL-15 NK
Drug: Cyclophosphamide

First Posted Date: 2023-10-16

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT06083883

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Relapsed/Refractory Large B-cell Lymphoma

Interventions: Drug: KITE-197
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-10-12

Last Posted Date: 2024-11-20

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 39

Registration Number: NCT06079164

Locations: 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States

and more 9 locations

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: Rimiducid
Drug: TROP2-CAR-NK Cells
Drug: Fludarabine phosphate
Drug: Cyclophosphamide

First Posted Date: 2023-10-04

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT06066424

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Myeloma

Interventions: Drug: Fludarabine phosphate
Drug: Cyclophosphamide
Drug: NY-ESO-1 TCR/IL-15 NK

First Posted Date: 2023-10-04

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT06066359

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: QH103 Cell Injection
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-09-28

Last Posted Date: 2023-10-24

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 10

Registration Number: NCT06056752

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Phase 1

Recruiting

Conditions: End Stage Renal Failure on Dialysis
Kidney Failure
Kidney Transplant

Interventions: Drug: Cyclophosphamide
Biological: CART-BCMA
Biological: huCART19
Drug: Fludarabine

First Posted Date: 2023-09-28

Last Posted Date: 2025-01-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT06056102

Locations: 🇺🇸
NYU Langone Health (Site #: 71177), New York, New York, United States
🇺🇸
Massachusetts General Hospital: Transplantation (Site #: 71107), Boston, Massachusetts, United States
🇺🇸
University of Pennsylvania Medical Center (Site #: 71111), Philadelphia, Pennsylvania, United States

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Phase 1

Recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Metastatic Pancreatic Adenocarcinoma
Metastatic Colorectal Adenocarcinoma

Interventions: Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Biological: T-cell Receptor-engineered T-cells

First Posted Date: 2023-09-21

Last Posted Date: 2024-11-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT06043713

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Biological: idecabtagene vicleucel
Drug: Lenalidomide
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-09-21

Last Posted Date: 2024-08-09

Lead Sponsor: Celgene

Target Recruit Count: 618

Registration Number: NCT06045806

Locations: 🇺🇸
Local Institution - 0147, Columbus, Ohio, United States
🇺🇸
Local Institution - 0102, Boston, Massachusetts, United States
🇩🇪
Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany

and more 118 locations

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: GSK3901961
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-09-21

Last Posted Date: 2024-11-13

Lead Sponsor: Adaptimmune

Target Recruit Count: 7

Registration Number: NCT06048705

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy